http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 08:50:41 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/CalciMedica+%28CALC%29+PT+Lowered+to+%2410+at+Oppenheimer/26115873.html Oppenheimer analyst Leland Gershall lowered the price target on CalciMedica (NASDAQ: CALC) to $10.00 (from $20.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/CalciMedica+%28CALC%29+PT+Lowered+to+%2410+at+Oppenheimer/26115873.html Thu, 05 Mar 2026 08:50:41 +0000 CALC http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CalciMedica%2C+Inc.++++++++++++++++++++/26103120.html si-local-file:///var/storage/secattach/20260303/26103120.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CalciMedica%2C+Inc.++++++++++++++++++++/26103120.html Tue, 03 Mar 2026 16:54:00 +0000 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CalciMedica%2C+Inc.++++++++++++++++++++/26103120.html si-local-file:///var/storage/secattach/20260303/26103120.html http://www.streetinsider.com/SEC+Filings/Form++S-3++++++++CalciMedica%2C+Inc.++++++++++++++++++++/26103120.html Tue, 03 Mar 2026 16:54:00 +0000 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26101353.html si-local-file:///var/storage/secattach/20260303/26101353.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26101353.html Tue, 03 Mar 2026 16:09:00 +0000 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26101353.html si-local-file:///var/storage/secattach/20260303/26101353.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++CalciMedica%2C+Inc.+++++++++For%3A+Dec+31/26101353.html Tue, 03 Mar 2026 16:09:00 +0000 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+02/26096420.html si-local-file:///var/storage/secattach/20260303/26096420.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+02/26096420.html Tue, 03 Mar 2026 07:16:00 +0000 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+02/26096420.html si-local-file:///var/storage/secattach/20260303/26096420.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+Mar+02/26096420.html Tue, 03 Mar 2026 07:16:00 +0000 CALC O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/Press+Releases/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html <div class="xn-content"> <p class="prntac"><i>Internal and external reviews of all available safety data from the Phase 2 KOURAGE trial in acute kidney injury (AKI) did not identify evidence of a drug-related toxicity with Auxora™</i></p><p class="prntac"><i>D</i><i>esign of pivotal program in acute pancreatitis (AP) expected in 1H 2026</i></p><p class="prntac"><i>JCI Insight publication of preclinical data demonstrates CM5480 as a potential differentiated therapy in pulmonary arterial hypertension (PAH); IND submission anticipated in 2027 </i></p><p><span class="legendSpanClass"><location value="LU/us.ca.lajlla" idsrc="xmltag.org" >LA JOLLA, Calif.</location></span>, <span class="legendSpanClass"><chron>March 3, 2026</chron></span> /PRNewswire/ -- <span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica Inc.</span> ("<span value="ACORN:4078229338" idsrc="xmltag.org" >CalciMedica</span>" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel http://www.streetinsider.com/PRNewswire/CalciMedica+Reports+2025+Financial+Results+and+Provides+Clinical+Updates/26096263.html Tue, 03 Mar 2026 07:00:00 +0000 A.06822034 A.40782293 CALC O.03198265 O.20026344 O.28976467 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Flynn+James+E/25963019.html si-local-file:///var/storage/secattach/20260206/25963019.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Flynn+James+E/25963019.html Fri, 06 Feb 2026 18:43:00 +0000 CALC O.28976467 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Flynn+James+E/25963019.html si-local-file:///var/storage/secattach/20260206/25963019.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++CalciMedica%2C+Inc.++++++++++++++++++++++Filed+by%3A+Flynn+James+E/25963019.html Fri, 06 Feb 2026 18:43:00 +0000 CALC O.28976467 http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+CalciMedica+%28CALC%29+to+Neutral/25911342.html (Updated - January 29, 2026 6:05 AM EST) <p>H.C. Wainwright analyst Joseph Pantginis downgraded CalciMedica (NASDAQ: CALC) from Buy to Neutral.</p><p>The analyst comments "Phase 2 KOURAGE study of Auxora in AKI discontinued. Yesterday, CalciMedica announced that it is discontinuing its Phase 2 KOURAGE clinical trial evaluating its lead clinical assets, Auxora, in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The decision comes after a recommendation by the trial's Independent Data Monitoring Committee (IDMC). Specifically, the IDMC cited a safety signal that warrants a re-evaluation of the Phase 2 study design, http://www.streetinsider.com/Downgrades/H.C.+Wainwright+Downgrades+CalciMedica+%28CALC%29+to+Neutral/25911342.html Thu, 29 Jan 2026 06:05:05 +0000 CALC http://www.streetinsider.com/Hot+Downgrades/H.C.+Wainwright+Downgrades+CalciMedica+%28CALC%29+to+Neutral/25911342.html (Updated - January 29, 2026 6:05 AM EST) <p>H.C. Wainwright analyst Joseph Pantginis downgraded CalciMedica (NASDAQ: CALC) from Buy to Neutral.</p><p>The analyst comments "Phase 2 KOURAGE study of Auxora in AKI discontinued. Yesterday, CalciMedica announced that it is discontinuing its Phase 2 KOURAGE clinical trial evaluating its lead clinical assets, Auxora, in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The decision comes after a recommendation by the trial's Independent Data Monitoring Committee (IDMC). Specifically, the IDMC cited a safety signal that warrants a re-evaluation of the Phase 2 study design, http://www.streetinsider.com/Hot+Downgrades/H.C.+Wainwright+Downgrades+CalciMedica+%28CALC%29+to+Neutral/25911342.html Thu, 29 Jan 2026 06:05:05 +0000 CALC http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Downgrades+CalciMedica+%28CALC%29+to+Neutral/25911342.html (Updated - January 29, 2026 6:05 AM EST) <p>H.C. Wainwright analyst Joseph Pantginis downgraded CalciMedica (NASDAQ: CALC) from Buy to Neutral.</p><p>The analyst comments "Phase 2 KOURAGE study of Auxora in AKI discontinued. Yesterday, CalciMedica announced that it is discontinuing its Phase 2 KOURAGE clinical trial evaluating its lead clinical assets, Auxora, in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). The decision comes after a recommendation by the trial's Independent Data Monitoring Committee (IDMC). Specifically, the IDMC cited a safety signal that warrants a re-evaluation of the Phase 2 study design, http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Downgrades+CalciMedica+%28CALC%29+to+Neutral/25911342.html Thu, 29 Jan 2026 06:05:05 +0000 CALC http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+Jan+28/25909977.html si-local-file:///var/storage/secattach/20260128/25909977.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++CalciMedica%2C+Inc.+++++++++For%3A+Jan+28/25909977.html Wed, 28 Jan 2026 17:29:00 +0000 CALC O.28976467